Table 2 Demographics, comorbid conditions and prosthesis use in all patients undergoing THA and for those revised within 8 years of surgery
Variable | All THA N = 151,113 | Revised N = 4415 |
|---|---|---|
Median (IQR) age in years | 73 (68-79) | 73 (67-78) |
N (%) female | 90,153 (59.7) | 2498 (56.6) |
N (%) cemented femoral | 66,537 (44) | 1534 (34.7) |
N (%) bearing surface | ||
 Ceramic/ceramic | 28,886 (19.1) | 1036 (23.5) |
 Ceramic/cross-linked polyethylene | 27,249 (18) | 698 (15.8) |
 Metal/cross-linked polyethylene | 94,978 (62.9) | 2681 (60.7) |
N (%) head size | ||
 ≤ 28 mm | 29,724 (19.7) | 995 (22.5) |
 32 mm | 64,854 (42.9) | 1761 (39.9) |
 36 mm | 53,376 (35.3) | 1558 (35.3) |
 ≥ 40 mm | 3159 (2.1) | 101 (2.3) |
N (%) anticoagulants | 20,990 (13.9) | 658 (14.9) |
N (%) antiplatelet medications | 27,645 (18.3) | 899 (20.4) |
N (%) anxiety | 16,146 (10.7) | 627 (14.2) |
N (%) arrhythmia | 9092 (6) | 290 (6.6) |
N (%) congestive heart failure | 11,708 (7.7) | 410 (9.3) |
N (%) depression | 37,159 (24.6) | 1402 (31.8) |
N (%) diabetes | 16,689 (11) | 494 (11.2) |
N (%) Gastro-oesophageal reflux disease | 65,911 (43.6) | 2194 (49.7) |
N (%) glaucoma | 9824 (6.5) | 286 (6.5) |
N (%) gout | 11,325 (7.5) | 372 (8.4) |
N (%) hyperlipidaemia | 70,365 (46.6) | 1990 (45.1) |
N (%) hypertension | 78,101 (51.7) | 2270 (51.4) |
N (%) hypothyroidism | 14,282 (9.5) | 430 (9.7) |
N (%) ischaemic heart disease (angina) | 9576 (6.3) | 309 (7) |
N (%) ischaemic heart disease (hypertension) | 50,495 (33.4) | 1512 (34.2) |
N (%) osteoporosis/Paget’s | 15,157 (10) | 501 (11.3) |
N (%) pain | 82,787 (54.8) | 2714 (61.5) |
N (%) inflammation pain | 83,078 (55) | 2714 (61.5) |
N (%) chronic airways disease | 29,633 (19.6) | 967 (21.9) |
N (%) steroid responsive | 22,730 (15) | 805 (18.2) |